National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension
试验速览
- 阶段
- 不适用
- 入组人数
- 3,600
- 试验地点
- 8
- 主要终点
- To recruit a national cohort (1000 subjects) of heritable, idiopathic PAH and PVOD/PCH cases.
研究概览
简要总结
Pulmonary arterial hypertension (PAH), or high blood pressure in the lungs, is a rare condition that can shorten life. Although the cause of this disease is usually unknown, in about 70% of heritable and 15-20% of idiopathic cases there is a change in a gene (a mutation) that controls how blood vessels grow and function. The gene is called bone morphogenetic protein type receptor 2 (BMPR2). Although mutations in BMPR2 are a risk factor for PAH, not everyone with a mutation gets the disease. Additional genetic and environmental factors are likely to contribute. The investigators suspect that mutations in other genes are responsible for some cases of PAH. In this study the investigators aim to recruit all patients with PAH and some of their relatives and follow them up for several years. The investigators hope to discover new mutations for this disease and to determine what factors lead to poor outcome, and to understand what triggers disease in patients with mutations.
Who can participate? Adults with PAH, their relatives and controls (one off blood sample)
详细描述
What does the study involve?
PAH patients will be seen at their local centre by their service team but they will have additional bloods taken. Relatives of PAH patients will be seen every year at their nearest PAH centre. Tests will include:
- Epidemiology Questionnaire to assess factors affecting health
- An echocardiogram (ECHO) to assess the size, shape, pumping action and the extent of any damage to the heart.
- Lung function tests which include blowing measurements to assess gas volumes within the lungs as well as assessment of how the lungs exchange gases.
- Optional right heart catheterisation (RHC) to determine how much blood your heart is pumping while you are resting and on exercise. Optional Cardiac Magnetic Resonance tests. To measure heart function. ( to be done only once)
- 6 minute walk test. To measure exercise capacity
- Cardiopulmonary exercise test. A bicycle exercise test, which will indicate how much blood your heart pumps while resting and with different levels of exercise.
- Electrocardiogram (ECG), a test that measures the electrical activity of the heart
- Blood tests
Controls:Blood sample and medical data collected once
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Inclusion Criteria-Patient
- •Participant is willing and able to give informed consent for participation in the study.
- •Male or Female, any age
- •Diagnosed with idiopathic, anorexigen-induced,heritable PAH, PVOD/PCH. Inclusion Criteria-Relative
- •Participant is willing and able to give informed consent for participation in the study.
- •Male or Female, any age
- •Has a family member diagnosed with idiopathic, anorexigen-induced, PVOD/PCH or heritable PAH
- •Exclusion Criteria-Patient
- •The participant may not enter the study if ANY of the following apply:
- •Patient is unable to give informed consent.
- •Not suffering from idiopathic, anorexigen-induced, PVOD/PCH or heritable PAH
- •Exclusion Criteria-Relative
- •The participant may not enter the study if ANY of the following apply:
- •Patient is unable to give informed consent.
- •Inclusion criteria-Controls
- •Participant is willing and able to give informed consent for participation in the study.
- •Self-reported to be healthy
- •Age range up to 75 years
排除标准
- 未提供
结局指标
主要结局
To recruit a national cohort (1000 subjects) of heritable, idiopathic PAH and PVOD/PCH cases.
时间窗: 8 years
The purpose of this study is to set up a national cohort of heritable, idiopathic PAH cases, PVOD/PCH and their relatives, to study the genetic and environmental contributions to disease. Setting up of this cohort of patients and relatives will provide the best resource for understanding what causes or triggers the disease, how to predict risk of death and response to therapy in individual patients, and to provide new ways of preventing and treating pulmonary arterial hypertension. The study will enable a better understanding for the first time the natural history of PAH, whether inherited or not. National outcomes to be measured will include survival, progression of the disease, changes in 6 minute walk distance, admissions to hospital for PAH and cause of death. Incidence of new cases of PAH will be measured in relatives as well.
次要结局
- To recruit PAH patients (1000) and family members to a Biorepository for serum/plasma and urine to identify biomarkers of disease onset, progression and response to treatment.(8 years)
研究者
Nick Morrell
BHF Professor of Cardiopulmonary Medicine
University of Cambridge